focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
I am surprised that you quit at this stage. Your comments help me a lot to hold this and now I am close to my average price. Wish you good luck... I am feeling positive Trading announcement tomorrow and we might see �15 soon...
I was watching every day this forum just quite and realized to keep patience for a long time to recover but seems, I don't need to wait for that long... I did not lose the hope and did not sold but still need another 35% up to reach my breakeven... I hope SP will touch �15 at some point this year.
Teva closed six plants last year and plan to close 6 plants this year of generics medicines. I feel similar closure will happen in a sector. If Hikma just sustains in this situation then in near future Generic sector will improve. Or you never know if Democrats come to power in the US then the situation for pharma sector will improve too...
Theoratically you right but seems market don't buy this idea. Sometimes if business don't cross breakeven costs thank goes to ground.. Currently this is not the case of Hikma. I have no set no other option but wait for another 3 years... As I am 50% down. I still believe Hikma will winner in longer run in 3 to 5 year's time frame... I will try to forget even I was having any money invested here...
Vectura Group Plc is uncertain whether revenue from its generic version of Advair will come in 2018, 2019 or 2020, after a delay in U.S. approval last year, CEO James Ward-Lilley said in an interview last month. Glaxo�s drug is forecast by analysts to generate about 2.2 billion pounds ($3.1 billion) in sales this year, according to data compiled by Bloomberg. U.K.-based Vectura and partner Hikma Pharmaceuticals Plc remain confident that their application will be approved �in due course,� a Vectura spokesman said. Shares of Novartis were down 0.5 percent at 11:32 a.m. after slipping as much as 1 percent in Zurich trading.